AB-103 is under clinical development by Jupiter Wellness and currently in Phase II for Alopecia. According to GlobalData, Phase II drugs for Alopecia have a 39% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how AB-103’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

AB-103 overview

AB-103 is under development for the treatment of alopecia. It is administered by topical route. The drug candidate acts by targeting follicular sulfotransferase (SULT1A1) and being developed as an adjuvant therapy to increase the effect of minoxidil.

Jupiter Wellness overview

Jupiter Wellness a company operates as a pharmaceutical company and the company manufactures products for physical and mental benefits. It is headquartered in Jupiter, Florida, the US.

For a complete picture of AB-103’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.